Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will present at the 15 th Annual BIO CEO & Investor Conference at 8:30 a.m. EST / 5:30 a.m. PST on Tuesday, February 12, 2013, in New York. During the presentation, Dr. Morrissey will review the company’s development plans and priorities for cabozantinib in 2013. He will also discuss the company’s corporate strategy and financial outlook, and provide a general business update. The presentation will be webcast and may be accessed via the Event Calendar page under Investors & Media at www.exelixis.com. About Exelixis Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on COMETRIQ™ (cabozantinib). Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at www.exelixis.com.